Ionis Pharmaceuticals (IONS) – Analysts’ Weekly Ratings Updates

Ionis Pharmaceuticals (NASDAQ: IONS) recently received a number of ratings updates from brokerages and research firms:

• 9/15/2026 – Ionis Pharmaceuticals had its price target lowered by Guggenheim from $89.00 to $80.00. They now have a “buy” rating on the stock.
• 9/9/2026 – Ionis Pharmaceuticals had its price target lowered by Barclays PLC from $90.00 to $85.00. They now have an “overweight” rating on the stock.
• 9/8/2026 – Ionis Pharmaceuticals had its “outperform” rating reaffirmed by Raymond James Financial, Inc.. They now have a $84.00 price target on the stock.
• 9/8/2026 – Ionis Pharmaceuticals had its price target lowered by Morgan Stanley from $110.00 to $104.00. They now have an “overweight” rating on the stock.
• 9/8/2026 – Ionis Pharmaceuticals had its “buy” rating reaffirmed by TD Cowen.
• 9/8/2026 – Ionis Pharmaceuticals had its price target lowered by BMO Capital Markets from $61.00 to $54.00. They now have a “market perform” rating on the stock.
• 9/8/2026 – Ionis Pharmaceuticals had its price target lowered by The Goldman Sachs Group, Inc. from $69.00 to $56.00. They now have a “neutral” rating on the stock.
• 9/8/2026 – Ionis Pharmaceuticals had its price target lowered by HC Wainwright from $115.00 to $100.00. They now have a “buy” rating on the stock.
• 9/8/2026 – Ionis Pharmaceuticals had its price target lowered by Canaccord Genuity Group Inc. from $95.00 to $85.00. They now have a “buy” rating on the stock.
• 9/4/2026 – Ionis Pharmaceuticals had its price target raised by BMO Capital Markets from $60.00 to $61.00. They now have a “market perform” rating on the stock.
• 9/4/2026 – Ionis Pharmaceuticals had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $86.00 price target on the stock.
• 8/31/2026 – Ionis Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $115.00 price target on the stock.
• 8/19/2026 – Ionis Pharmaceuticals is now covered by BMO Capital Markets. They set a “market perform” rating and a $60.00 price target on the stock.
• 8/18/2026 – Ionis Pharmaceuticals was upgraded by BMO Capital Markets to “hold”.
• 8/3/2026 – Ionis Pharmaceuticals had its price target raised by JPMorgan Chase & Co. from $72.00 to $76.00. They now have an “overweight” rating on the stock.
• 8/1/2026 – Ionis Pharmaceuticals was downgraded by Wall Street Zen from “hold” to “sell”.
• 7/30/2026 – Ionis Pharmaceuticals had its price target lowered by Wells Fargo & Company from $100.00 to $95.00. They now have an “overweight” rating on the stock.
• 7/30/2026 – Ionis Pharmaceuticals had its price target lowered by HC Wainwright from $125.00 to $115.00. They now have a “buy” rating on the stock.
• 7/29/2026 – Ionis Pharmaceuticals had its “neutral” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $69.00 price target on the stock.
• 7/23/2026 – Ionis Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright.
• 7/21/2026 – Ionis Pharmaceuticals had its price target lowered by Guggenheim from $106.00 to $89.00. They now have a “buy” rating on the stock.

Insider Activity at Ionis Pharmaceuticals

In related news, CEO Brett P. Monia sold 50,000 shares of Ionis Pharmaceuticals stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $80.59, for a total value of $4,029,500.00. Following the sale, the chief executive officer directly owned 245,571 shares in the company, valued at $19,790,566.89. This trade represents a 16.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP C. Bennett sold 15,000 shares of the business’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $85.46, for a total transaction of $1,281,900.00. Following the transaction, the executive vice president directly owned 75,018 shares of the company’s stock, valued at $6,411,038.28. The trade was a 16.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 156,317 shares of company stock valued at $12,656,566. Company insiders own 1.81% of the company’s stock.

Ionis Pharmaceuticals, Inc is a biotechnology company that discovers and develops medicines using antisense technology, which is designed to target RNA and influence the production of disease-related proteins. The company focuses on neurological, cardiovascular, metabolic and other serious diseases for which there remains a significant unmet medical need.

Ionis has developed several approved therapies, including SPINRAZA (nusinersen) for spinal muscular atrophy, QALSODY (tofersen) for a form of amyotrophic lateral sclerosis, TEGSEDI (inotersen) for hereditary transthyretin-mediated amyloidosis and WAYLIVRA (volanesorsen) for familial chylomicronemia syndrome in certain markets.